Sipai Health Technology Co., Ltd. (0314.HK) Stock

About Sipai Health Technology Co., Ltd.

Sipai Health Technology Co., Ltd. is a Chinese enterprise specializing in medical technology and health management. Its business operations are diversified across three primary divisions: Specialty Pharmacy, Physician Research Assistance, and Health Insurance Services. The Specialty Pharmacy division manages a network of dedicated pharmacies and is also involved in the distribution of pharmaceutical products to drug manufacturers and other supply chain partners. Through its Physician Research Assistance segment, Sipai Health provides comprehensive site management organization (SMO) support to pharmaceutical firms and clinical research institutions. These services encompass a broad spectrum, including site identification and setup, patient acquisition and oversight, data and document handling, on-site logistical management of drugs and biosamples, and trial conclusion. Additionally, this segment offers specialized image management for clinical studies. The Health Insurance Services division functions as an intermediary, delivering brokerage solutions to various insurance providers. Established in 2014, the company's headquarters are situated in Guangzhou, China.

Sipai Health Technology Co., Ltd. is led by CEO Xuguang Ma, employs 3,131 people, headquartered in Shanghai, CN, publicly traded since 2022.

over the past 52 weeks the stock has ranged between $1.13 and $6.10, and currently trades 76.9% below its 52-week high.

Official website: www.medbankshealthtech.com